ICU Medical Inc/de: insider trades · United States · SEC (Form 4)

About ICU Medical Inc/de

ICU Medical, Inc. (Nasdaq: ICUI) is a U.S.-based medical technology company focused on infusion therapy, vascular access, and critical care applications. The company is listed on the NASDAQ market in the United States, was founded in 1984, and is headquartered in San Clemente, California. For international investors, the company sits in a specialized but essential part of the healthcare supply chain: its devices are used daily in hospitals and other care settings for IV therapy, medication safety, monitoring, and selected critical care workflows. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai)) ICU Medical built its franchise first around infusion-related products and then expanded through internal development and acquisitions. Key milestones include the purchase of Hospira Infusion Systems, which broadened the company’s pump and consumables portfolio, and later the Smiths Medical acquisition, which added syringe and ambulatory infusion devices, vascular access products, and vital care offerings. More recently, ICU Medical restructured part of its portfolio through a joint venture with Otsuka Pharmaceutical Factory around the IV Solutions business, aimed at improving manufacturing capability and sharpening the company’s long-term operating profile. ([ir.icumed.com](https://ir.icumed.com/news-releases/news-release-details/icu-medical-inc-acquire-hospira-infusion-systems-business-pfizer?utm_source=openai)) From a business-model perspective, ICU Medical is best understood as an integrated platform in infusion and adjacent clinical areas. Its portfolio includes IV smart pumps, infusion sets, needlefree connectors, peripheral IV catheters, sterile IV solutions, closed-system transfer devices for hazardous drugs, pharmacy compounding systems, and a range of respiratory, anesthesia, patient monitoring, and temperature-management products. The company also sells certain products on an OEM basis to other medical-device manufacturers. This breadth gives ICU Medical meaningful exposure across acute care, alternative-site care, and, in some cases, home-care settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai)) In competitive terms, ICU Medical is often framed as a “pure-play” infusion leader with a broader global footprint than in its early years. Its competitive strengths come from the breadth of its offering, technical depth in consumables, clinical safety features, and long-standing customer relationships with hospitals and healthcare systems. The company’s geographic reach has expanded materially through acquisitions, with sales and operations spanning the United States and international markets. ([ir.icumed.com](https://ir.icumed.com/news-releases/news-release-details/icu-medical-completes-acquisition-hospira-infusion-systems?utm_source=openai)) Recent developments have centered on portfolio integration and operating improvement. In 2025 and 2026, management highlighted continued Smiths Medical integration work, the formation of the IV Solutions joint venture with Otsuka, and a focus on organic growth, manufacturing execution, and capital discipline. The company also released fourth-quarter 2025 results and 2026 guidance in early 2026, underscoring that ICU Medical remains in a multi-year transformation phase following major portfolio reshaping. For equity investors, that makes the story a combination of defensive healthcare exposure and an execution-focused industrial turnaround within medical technology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398426000008/icui-20251231.htm?utm_source=openai))